Boston Scientific Announces First Implantations of OMEGA(TM) Platinum Chromium Coronary Stent System in the UK

Third-Generation Bare-Metal Stent Implanted in the UK

HEMEL HEMPSTEAD, England, March 23, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced the
first implant in the UK of the OMEGA(TM) Platinum Chromium Bare-Metal
Coronary Stent System which recently received CE Mark approval. The first
implant was performed by Dr Neal Uren, Consultant Cardiologist, Royal
Infirmary of Edinburgh.

The OMEGA Stent System incorporates a unique platinum
chromium (PtCr) alloy designed specifically for coronary stenting and is
intended to provide interventional cardiologists a bare-metal stent with
improved acute performance in treating patients with coronary artery disease.

"Omega is a highly deliverable stent, with fantastic conformability to
the natural shape of the vessel. The Platinum Chromium alloy also provides
excellent strength and radiopacity. In my opinion, these qualities highlight
Omega as a definite step-up in the Bare Metal stent market" said Dr. Neal
Uren

The OMEGA Stent System is part of the Company's PtCr Stent
series, which includes the TAXUS(R) Element(TM) Paclitaxel-Eluting Stent and
PROMUS Element(TM) Everolimus-Eluting Stent Systems. All three stents feature
the novel PtCr alloy and an innovative stent design, which combine to offer
greater radial strength and flexibility while reducing stent recoil. The
higher density alloy provides superior visibility while permitting thinner
struts compared to prior-generation stents[1]. The enhanced delivery system
features a dual-layer balloon and is engineered to improve access to
challenging lesions.

The OMEGA Stent is offered in 48 different sizes ranging in
diameter from 2.25 mm to 4.50 mm and lengths of 8 mm to 32 mm.

"The platinum chromium PROMUS Element Stent has been well received by UK
Interventional Cardiologists since its launch in November 2009, and we are
pleased to offer a bare-metal coronary stent built on the same PtCr
platform," said Tim Coutts, General Manager, UK Group, Boston Scientific.
"The OMEGA Stent is the latest example of our commitment to continued
innovation in coronary stenting. We are confident our platinum chromium
technology will strengthen our leadership position in the UK Interventional
Cardiology Market."

Cardiovascular disease (CVD) is one of the main causes of
death in Europe and the European Union (EU)[2]. Over a third of deaths from
CVD are from Coronary Heart Diseases (CHD). CHD is the most common cause of
death in the EU.

Coronary artery disease (CAD) occurs when atherosclerotic
plaque (hardening of the arteries) builds up in the wall of the arteries that
supply blood to the heart. The atherosclerotic process causes significant
narrowing in one or more coronary arteries - and if this is followed by the
formation of a blot clot (thrombus) on top of the plaque, the artery becomes
completely blocked which may cause a heart attack. The interruption of oxygen
and nutrition supply due to a heart attack leads to ischemia and subsequent
necrosis of heart tissue and can lead to the death of the affected person.

CAD can be treated with either combination of drug therapy and
coronary artery bypass grafting (CABG) or percutaneous coronary intervention
(PCI), also known as angioplasty. PCI is the use of balloon angioplasty and
bare-metal stents (BMS) or drug-eluting stents (DES), a stent coated with a
drug. This procedure generally takes about 90 minutes and is done with local
anaesthesia on patients who are mildly sedated.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding clinical trials, regulatory
approvals, competitive offerings, product performance and our market
position. If our underlying assumptions turn out to be incorrect, or if
certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have affected and
in the future (together with other factors) could affect our ability to
implement our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue reliance on
any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT:

    Mark McIntyre
    Boston Scientific Ltd
    Director Public Affairs
    +44(0)7717-300167

    [1] Based on bench testing. Data on file with Boston Scientific.
    [2] www.who.int/cardiovascular_diseases/resources/atlas/en/

CONTACT: Mark McIntyre, Boston Scientific Ltd, Director Public Affairs, +44(0)7717-300167